HYAL'S AT2101 NOW AVAILABLE IN CANADA
Hyal Pharmaceutical has announced that its analgesic drug Hyal-AT2101 is now available to patients in Canada under the country's emergency drug release program. The company said that it was making the drug, to be called Hyanalgese, available in advance of formal marketing approval because of a high level of demand from both patients and doctors.
Hyanalgese is topical cream applied to the skin to relieve the chronic pain of osteoarthritis. Phase III trials on the product are ongoing in Canada, the USA and the UK.
- Meantime, Hyal has sold an option to Ciba-Geigy Canada, giving the latter company the exclusive right, for a period of six months, to evaluate and license Hyanalgese in Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze